Elanco Animal Health (NYSE:ELAN) Price Target Raised to $30.00

Elanco Animal Health (NYSE:ELAN) had its price target boosted by Leerink Partners from $26.00 to $30.00 in a research report sent to investors on Tuesday,Benzinga reports. They currently have an outperform rating on the stock.

A number of other analysts also recently commented on ELAN. Barclays started coverage on shares of Elanco Animal Health in a report on Tuesday, December 9th. They set an “overweight” rating and a $30.00 price objective on the stock. Zacks Research lowered Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 6th. KeyCorp reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, December 10th. UBS Group lifted their price objective on Elanco Animal Health from $27.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. Finally, Argus raised Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.67.

Elanco Animal Health Stock Down 2.5%

Elanco Animal Health stock opened at $26.17 on Tuesday. The stock’s 50 day moving average price is $24.15 and its 200 day moving average price is $21.69. Elanco Animal Health has a 1-year low of $8.02 and a 1-year high of $27.72. The company has a market cap of $13.01 billion, a PE ratio of -54.52, a price-to-earnings-growth ratio of 3.98 and a beta of 1.87. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.17 and a quick ratio of 1.23.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.02. The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.Elanco Animal Health’s revenue was up 12.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.14 earnings per share. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. On average, sell-side analysts predict that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Robert M. Vanhimbergen acquired 6,950 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was purchased at an average price of $21.64 per share, for a total transaction of $150,398.00. Following the transaction, the chief financial officer owned 124,233 shares in the company, valued at $2,688,402.12. This trade represents a 5.93% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Lawrence Erik Kurzius bought 10,000 shares of Elanco Animal Health stock in a transaction on Friday, December 12th. The stock was purchased at an average price of $21.30 per share, for a total transaction of $213,000.00. Following the completion of the acquisition, the director owned 131,773 shares in the company, valued at $2,806,764.90. This represents a 8.21% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders purchased 43,450 shares of company stock worth $937,883. 0.89% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Elanco Animal Health

Institutional investors have recently modified their holdings of the company. Hsbc Holdings PLC increased its stake in Elanco Animal Health by 434.2% in the second quarter. Hsbc Holdings PLC now owns 126,334 shares of the company’s stock valued at $1,801,000 after purchasing an additional 102,686 shares during the last quarter. Norges Bank purchased a new stake in Elanco Animal Health in the 2nd quarter valued at about $12,502,000. Amalgamated Bank increased its stake in shares of Elanco Animal Health by 793.7% during the 3rd quarter. Amalgamated Bank now owns 226,580 shares of the company’s stock valued at $4,563,000 after acquiring an additional 201,226 shares during the last quarter. Independent Advisor Alliance lifted its holdings in shares of Elanco Animal Health by 364.5% during the 3rd quarter. Independent Advisor Alliance now owns 98,025 shares of the company’s stock worth $1,974,000 after acquiring an additional 76,920 shares during the period. Finally, State of Michigan Retirement System acquired a new stake in shares of Elanco Animal Health in the third quarter worth approximately $2,383,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Key Elanco Animal Health News

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Q4 earnings beat and upbeat outlook: Elanco reported stronger-than-expected Q4 revenue and an EPS beat, gave Q1 and FY 2026 EPS guidance, and the stock hit a new 12‑month high on the reaction. This is the primary fundamental driver of the recent rally. Elanco Animal Health Inc (ELAN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst …
• Positive Sentiment: Analyst bullishness: Multiple firms raised targets — KeyCorp boosted its PT to $29 (overweight) and Leerink raised its PT to $30 — reinforcing upside expectations and supporting investor sentiment. ‘Elanco Animal Health (ELAN) set up well for beats and raises’; PT Raised to $29 at KeyBanc Leerink Partners Boosts Elanco Animal Health (NYSE:ELAN) Price Target to $30.00
• Positive Sentiment: Short interest fell materially in February (down ~20.7%), reducing a source of selling pressure and lowering the potential for short-driven downside. (Data summarized in filings/market reports.)
• Positive Sentiment: High-profile media coverage: Jim Cramer highlighted Elanco’s “comeback story” and CEO Jeff Simmons appeared in an interview, increasing retail/institutional visibility and demand. Jim Cramer Highlights Elanco’s “Comeback Story” Elanco Animal Health CEO Jeff Simmons goes one-on-one with Jim Cramer
• Neutral Sentiment: Investor presentation: Elanco presented at the BofA Securities Animal Health Summit (transcript available) — useful for modelers but less immediately market-moving than earnings and PT changes. Elanco Animal Health Incorporated (ELAN) Presents at BofA Securities Animal Health Summit Transcript
• Neutral Sentiment: Strategic collaboration in Japan: Amlan International and Elanco are running calf‑health educational seminars in Japan — a positive commercial/branding initiative but unlikely to move near‑term results materially. Amlan International and Elanco Collaborate on Japanese Educational Seminars Focused on Calf Health
• Negative Sentiment: More conservative shop: Morgan Stanley raised its price target modestly to $24 but kept an “equal weight” rating — that PT sits below recent market price and signals at least one analyst sees limited near‑term upside. Morgan Stanley Issues Positive Forecast for Elanco Animal Health (NYSE:ELAN) Stock Price

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.